Sudden Cardiac Death in Patients with Heart Disease and Preserved Systolic Function: Current Options for Risk

Luigi Pannone1, Giulio Falasconi1, Lorenzo Cianfanelli1

  • 1Cardiology Department, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.

Insights

Sudden cardiac death (SCD) risk is high in patients with preserved or mid-range ejection fraction. This review details current risk stratification strategies for identifying patients who need implantable cardioverter-defibrillators (ICDs).

Area of Science:

  • Cardiology
  • Electrophysiology
  • Cardiovascular Medicine

Background:

  • Sudden cardiac death (SCD) is a major cause of mortality in coronary artery disease and heart failure with preserved ejection fraction.
  • Patients with preserved or mid-range left ventricular ejection fraction (LVEF >35%) experience a higher absolute number of SCDs globally.
  • Current guidelines lack specific recommendations for SCD risk reduction in this patient group.

Purpose of the Study:

  • To provide a comprehensive overview of current state-of-the-art risk stratification for SCD.
  • To identify patients with mid-range or preserved LVEF who may benefit from implantable cardioverter-defibrillator (ICD) implantation.
  • To focus on specific etiologies including ischemic cardiomyopathy, heart failure, atrial fibrillation, and myocarditis.

Main Methods:

  • Review of existing literature and ongoing advancements in risk stratification techniques.
  • Analysis of electrophysiological and imaging modalities for patient identification.
  • Focus on evidence-based approaches for SCD prevention.

Main Results:

  • Improvements in risk stratification are enhancing the identification of high-risk individuals.
  • Electrophysiological and imaging techniques show promise for personalized risk assessment.
  • There remains an unmet need for clear guidelines on ICD implantation in this population.

Conclusions:

  • Accurate SCD risk stratification is crucial for patients with preserved or mid-range LVEF.
  • Advanced techniques are improving the ability to identify candidates for ICD therapy.
  • Further research and guideline development are needed to address SCD prevention in this growing patient cohort.

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
108
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
117
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
68
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
102
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
118
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
646